Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Cancers|March 11, 2023
Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter StudyTeresa Caballero-Velázquez, Olga Pérez-López, Ana Yeguas Bermejo, et al.
Kidney International|September 16, 2017
A retrospective study of pregnancy-associated atypical hemolytic uremic syndromeAna Huerta, Emilia Arjona, Jose Portoles, et al.
Annals of Hematology|September 22, 2011
Prognostic value of cytogenetics in adult patients with Philadelphia-negative acute lymphoblastic leukemiaInés Gómez-Seguí, Jose Cervera, Esperanza Such, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 15, 2011
Significance of increased blastic-appearing cells in bone marrow following myeloablative unrelated cord blood transplantation in adult patientsPau Montesinos, Adriana Gascón, David Martínez-Cuadrón, et al.
Annals of Hematology|June 27, 2019
Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxisRebeca Rodríguez-Veiga, Pau Montesinos, Blanca Boluda, et al.
Annals of Hematology|February 3, 2018
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemiaDavid Martínez-Cuadrón, Blanca Boluda, Pilar Martínez, et al.
Annals of Hematology|February 24, 2018
Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemiaDavid Martínez-Cuadrón, Blanca Boluda, Pilar Martínez, et al.
Hemasphere|October 7, 2025
Patterns of immune recovery after axicabtagene ciloleucel for aggressive B-cell lymphomaAndré Airosa Pardal, Ana Benzaquén, Pablo Granados, et al.
European Journal of Haematology|February 20, 2021
Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from SpainAntonio Solana-Altabella, Blanca Boluda, Rebeca Rodríguez-Veiga, et al.
Annals of Hematology|April 29, 2021
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patientsMaría P Martínez Sánchez, Juan Eduardo Megías-Vericat, Rebeca Rodríguez-Veiga, et al.
Pageof 4